Lab-Grown stem cells could unlock secrets of scleroderma
NCT ID NCT07650565
First seen Jun 16, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This study will take blood samples from 16 people—some with severe scleroderma, some with mild forms, and their healthy relatives—to create stem cells in the lab. These stem cells will be turned into different cell types (like heart, skin, and immune cells) to study how the disease works at a cellular level. The goal is to better understand why scleroderma varies so much between patients, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University hospital Montpellier
Montpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could reveal why scleroderma affects people differently and point toward new targets for future treatments.
What could go wrong
This is a very early, small study (16 people) focused on building lab models, not testing treatments. It may not lead directly to any therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.